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Autophagy 
 
●  Autophagy is a catabolic process that degrades and recycles 
damaged organelles and macromolecules within the cell 
○  Autophagy is generally seen survival mechanism.  
●  Autophagy plays a key role in preventing diseases 
○  It have also shown autophagy to be a tumor suppressive 
mechanism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DNA Methylation 
●  DNA methylation is an epigenetic mechanism involving the transfer 
of a methyl group onto the C5 position of the cytosine to form 5-
methylcytosine 
○  DNA methylation regulates gene expression  
●  These epigenetic modifications, such as DNA methylation have 
shown to be a part of carcinogenesis  
●  Promoter methylation may silence crucial genes that have been 
shown to regulate autophagy in cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prostate Cancer 
●  Prostate cancer is the most frequent tumor found in men worldwide  
●  Previous studies have shown clear indications that stable 
epigenomic changes occur in cells of prostate cancer.  
●  One of the most occurring events in prostate cancer is DNA 
methylation. 
●  There may be a strong relationship in biological mechanisms and 
pathways between promoter methylation in autophagy genes and 
prostate cancer.  
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
NAS Data 
•  The Normative Aging Study (NAS) was established by the US 
Department of Veteran Affairs (VA) in 1963  
•  981 participants died and 470 were lost to follow up. 
•  Participants were recalled for clinical examinations every 3–5 years 
•  Starting in 1999, these included 7-ml blood samples for DNA 
analysis.  
•  This study was approved by the Institutional Review Boards of all 
participating institutions, and all participants provided written 
consent. 
 
NAS Data (cont.) 
•  Only cancer-free participants and participants with prostate cancer 
were considered  
•  36 (28.8%) had prostate cancer, while the remaining population had 
digestive, skin, respiratory, and other cancers. 
•  The remaining population of 402 participants was 
further limited due to the nature of the all-male cohort.  
•  The participants were then split into 3 groups based off the amount 
of years before their diagnosis date: 0-4 years, 4-8 years, and 8+ 
years from their baseline date.  
•  Information on cancer diagnosis was obtained from questionnaires 
and confirmed via review of medical records. 
 
Initial Analysis 
•  Each group included the cancer-free participants for a comparison 
analysis between the beta values that measure DNA methylation.  
•  354 cancer-free participants, 0-4 years had 28 cancer participants, 
4-8 years had 9 cancer participants, and 8+ years had 6 cancer 
participants. 
•  Each group was run through a robust linear regression and linear 
regression model to get better insight into the significant CpG sites.  
•  Only the CpGs that were significant between at least 2 of the groups 
were considered and compared to understand the DNA methylation 
changes.  
 
Initial Analysis (cont.) 
•  All models were adjusted for age, education, BMI, and cell 
proportion.  
•  Each group included the cancer-free participants for a comparison 
analysis between the beta values that measure DNA methylation.  
•  Each group was run through a robust linear regression and linear 
regression model to get better insight into the significant CpG sites.  
•  Only the CpGs that were significant between at least 2 of the groups 
were considered and compared to understand the DNA methylation 
changes.  
 
 
 
Final Analysis 
•  The robust linear regression model was later used to compare 
between the groups.  
•  Smoke years and alcohol consumption did not appreciably affect our 
results, prompting their exclusion.  
•  Participants missing any data for outcome was discluded 
•  Figures were generated using R v3.5.1.  
•  Statistical significance threshold was set to p = 0.01.  
•  Sensitivity analyses and KEGG Pathway tests were run in order to 
gain better insight into the significance of the results. 
•  All models were adjusted for age, education, BMI, and cell 
proportion.  
 
 
Sensitivity and Genomic 
Analysis 
•  The purpose of the sensitivity analysis is to test the robustness of the 
model. 
•  A crude model was compared with the adjusted model to verify the 
significance of the results. 
•  Each showed a strong, positive correlation with r > 0.9. 
•  Each CpG site showed a consistency between their respective 
groups.  
•  For Years 8+ and Years 0-4, the sensitivity analysis showed a 
stronger correlation (r=0.959, r=0.969) compared to Years 4-8 (r = 
0.942). 
•  The genomic analysis failed to report anything significant to report 
to further strengthen the results.  
KEGG Pathway Analysis 
•  Using the significant 22 CpG sites, 60 gene pathways were identified 
by using the KEGG and statistical tests.  
•  15 of the pathways were significant (p-value < 0.05).  
•  The most significant pathways include necroptosis, calcium signaling 
pathway, insulin secretion, circadian entrainment, gastric acid 
secretion, and aldosterone synthesis and secretion (p < 0.01) 
•  Mechanisms and regulation of necroptosis affects tumorigenesis 
•  Calcium signaling has been showing signs of providing an effective 
diagnosis and treatment of prostate cancer.  
Conclusions 
•  The robust linear model located 2,113 significant CpG sites.  
•  The 22 significant and directionally consistent CpG sites were 
considered further, and were limited down to 12 genes to consider 
only the CpG sites that lied on the promoter region. 
•  Previous studies have shown significant results for the 12 genes that 
the CpG sites lie on. 
•  HSP27, SQSTM1, TFEB, REL, VDAC1 remain consistent with my 
findings  
•  KRT74z, PRKCZ, SNORA84, TMEM49, SLC7A6, and BRSK2 are novel 
biomarkers that need further research in order to verify their 
autophagic effects in prostate cancer. 
Conclusions (cont.) 
•  The work in the field of autophagy and its relationship to cancer is 
growing, as the complex associations and relationships between 
autophagy and cancer are being explored.  
•  This paper seeks to further clarify the relationship by verifying some 
previously known mechanisms 
•  This prospective study design allows pediatricians and 
pharmaceutical companies to utilize this information and target these 
biomarkers beforehand to develop a better prognosis and treatment 
plan.  
 
 
 
 
	
Future Research 
•  Research into both calcium signaling and necroptosis molecular 
mechanisms could potentially yield new biomarkers for researchers 
to utilize.  
•  The relationships between the functionality of autophagy and these 
pathways to prostate cancer to create effective prognosis and 
treatment methods for the future. 
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